Ultiva

Ultiva

remifentanil

Manufacturer:

Aspen

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Remifentanil HCl
Indications/Uses
Analgesic agent during induction &/or maintenance of general anaesth during surgical procedures including cardiac surgery; continuation of analgesia into immediate post-op period during transition to longer-acting analgesia. Provision of analgesia & sedation in mechanically ventilated intensive care patients.
Dosage/Direction for Use
Adult General anaesth induction 0.5-1 mcg/kg/min w/ or w/o initial bolus infusion of 1 mcg/kg over not <30 sec. Maintenance Dosage may be decreased individually & supplemental bolus infusion may be administered every 2-5 min. Spontaneously breathing anaesthetised patient w/ secured airway Initially 0.04 mcg/kg/min. Continuation into immediate post-op period Patient breathing spontaneously Initially, decrease infusion rate to 0.1 mcg/kg/min, may then be increased or decreased by not >0.025 mcg/kg/min every 5 min. Cardiac anaesth induction Initially 1 mcg/kg/min. Maintenance 0.5 mcg/kg. Intensive care patient Initially 0.1-0.15 mcg/kg/min, titrated in increments of 0.025 mcg/kg/min. Further increase in increments of 0.025 mcg/kg/min if additional analgesia is required. Additional analgesia for ventilated patient undergoing stimulation procedures Maintain 0.1 mcg/kg/min for at least 5 min prior to procedure, may be adjusted every 2-5 min. Max: 0.75 mcg/kg/min.
Contraindications
Hypersensitivity to remifentanil HCl, other fentanyl analogues. Epidural & intrathecal use.
Special Precautions
Hypersensitivity to opioids. Not for epidural or intrathecal inj. Not recommended for use as sole agent in general anaesth. Muscle rigidity; marked resp depression; hypotension, bradycardia; drug dependency. Administer analgesics prior to or immediately following discontinuation of treatment in patients undergoing surgical procedures w/ anticipated post-op pain. ASA III/IV patients. Inadvertent administration. Avoid abrupt discontinuation. Concomitant use w/ benzodiazepines. May affect ability to drive & use machines. Severe hepatic impairment. Pregnancy & lactation. Debilitated, hypovolaemic & elderly patients.
Adverse Reactions
Skeletal muscle rigidity; hypotension; nausea, vomiting. Bradycardia; post-op HTN; acute resp depression, apnoea; pruritus; post-op shivering.
Drug Interactions
Decreased amount or dose of inhaled & IV anaesth & benzodiazepines required for anaesth. Exacerbated CV effects eg, hypotension, bradycardia w/ cardiac depressants drugs eg, β-blockers & Ca-channel blockers. Additive pharmacologic effect w/ benzodiazepines. Incompatibility w/ lactated ringer’s, dextrose, propofol, blood/serum/plasma.
MIMS Class
Anaesthetics - Local & General
ATC Classification
N01AH06 - remifentanil ; Belongs to the class of opioid anesthetics. Used as general anesthetics.
Presentation/Packing
Form
Ultiva powd for inj 1 mg
Packing/Price
5 × 1's
Form
Ultiva powd for inj 5 mg
Packing/Price
5 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in